Recent news highlights Cooper Companies' Q2 fiscal 2026 earnings beat with revenue rising 8%, despite a net loss driven by a one-time litigation charge related to a product recall. The company trimmed its full-year 2026 revenue guidance. Management has reached settlement agreements covering over 95% of claimants in the litigation. The company continues to navigate operational challenges including supply chain and inflationary pressures.

• Cooper Companies reported Q2 fiscal 2026 results with an 8% revenue increase but a net loss due to a one-time litigation charge related to a product recall [N5].
• The company’s Q2 earnings beat expectations, and revenue guidance for fiscal 2026 was trimmed [N1][N4].
• Management reached settlement agreements covering over 95% of claimants related to the embryo culture media litigation, with a net charge of $271.6 million recorded [S2][N5].
• The company is continuing its multiyear ERP system implementation across CooperVision and CooperSurgical [N2].
• Supply chain constraints, inflation, and labor shortages remain operational challenges [N3].
• The share repurchase program remains active with $860.8 million authorized for repurchase as of April 30, 2026 [S2].

The company has demonstrated resilience with revenue growth of 8% in Q2 fiscal 2026 despite a one-time litigation charge. Its global manufacturing and distribution network supports broad market access. The ongoing ERP implementation and manufacturing process improvements could enhance operational efficiency. The company’s ability to settle the majority of litigation claims related to the embryo culture media recall reduces uncertainty. The share repurchase program indicates management's confidence in capital allocation. Continued international sales contribute materially to total revenue, supporting diversification.

The company faces significant risks including a net loss in Q2 fiscal 2026 driven by a substantial litigation charge related to a product recall, with over 140 lawsuits filed. Supply chain disruptions, inflationary pressures, and labor shortages could adversely impact costs and product availability. Regulatory compliance complexities and geopolitical risks in international markets add uncertainty. The ERP system implementation is complex and costly, with potential operational disruptions. Customer base consolidation increases dependency on large accounts, heightening business concentration risk. Indebtedness and restrictive credit covenants may limit financial flexibility.

Cooper Companies benefits from a diversified global manufacturing and distribution footprint, established customer relationships with large healthcare providers and retail chains, and a portfolio of specialized medical device products including silicone hydrogel contact lenses and fertility-related surgical products. The company's scale and product breadth provide competitive advantages in manufacturing efficiency and market reach. However, the business faces pricing pressures from competitors and customers, regulatory hurdles, and risks related to supply chain dependencies and product recalls. Its ongoing investments in manufacturing process improvements and ERP systems aim to sustain operational efficiency and product quality.

• Litigation and Product Recall Risks: The company faces ongoing litigation related to a voluntary recall of embryo culture media by CooperSurgical, with over 140 lawsuits filed and a $271.6 million net charge recorded in fiscal 2026. This litigation poses financial and reputational risks.
• Supply Chain and Manufacturing Disruptions: Dependence on key suppliers and manufacturing sites, some of which are sole sources for critical materials, exposes the company to risks of inventory shortages and production delays. Disruptions could materially affect sales and profitability.
• Regulatory and Compliance Risks: The company operates under complex regulatory frameworks including FDA, EU MDR, and international laws. Changes in regulations or failure to comply could increase costs, delay product approvals, or restrict market access.
• Economic and Geopolitical Risks: Inflation, labor shortages, currency fluctuations, trade sanctions, tariffs, and geopolitical conflicts may adversely impact costs, revenues, and international operations.
• ERP System Implementation Risks: The multiyear ERP system implementation is complex and costly, with potential for operational disruptions and increased expenses if not successfully executed.
• Customer Concentration and Pricing Pressure: Consolidation of customer bases into larger accounts increases business concentration risk. Competitive pricing pressures and changes in third-party reimbursement may reduce demand and margins.
• Financial and Liquidity Risks: Significant indebtedness and restrictive covenants may limit financial flexibility. Liquidity depends on operating cash flow and access to capital markets, which may be affected by economic conditions.
• Cybersecurity Risks: Increasing frequency and sophistication of cyberattacks pose risks of data breaches, operational disruptions, and financial and reputational harm despite existing security measures.

• Cooper Companies, Inc. operates two main business units: CooperVision and CooperSurgical, manufacturing and distributing medical devices including contact lenses and fertility-related products.
• The company has significant manufacturing and distribution operations globally, including in North America, Latin America, and Europe.
• Approximately half of net sales for fiscal years 2024 and 2025 were from outside the United States.
• CooperVision manufactures molded contact lenses primarily at facilities in Costa Rica, Hungary, Puerto Rico, the UK, and the US.
• CooperSurgical manufactures most products in Costa Rica, the UK, and the US, with additional smaller locations worldwide.
• The company faces risks from customer base consolidation, with larger global and regional key accounts representing a larger proportion of business.
• Inflation, supply chain constraints, labor shortages, and geopolitical issues have impacted costs and revenues.
• The company is subject to extensive regulatory requirements including FDA, EU MDR, and other international laws.
• CooperCompanies has ongoing litigation related to a voluntary recall of embryo culture media by CooperSurgical, with over 140 lawsuits filed and a $271.6 million net charge recorded in fiscal 2026.
• The company has a share repurchase program authorized up to $2.0 billion, with $860.8 million remaining as of April 30, 2026.
• Liquidity ratios as of April 30, 2026: current ratio 1.27, cash ratio 0.08, cash and equivalents $138.8 million, current assets $2.3 billion, current liabilities $1.8 billion.
• For Q2 fiscal 2026 ended April 30, the company reported a net loss of $77.9 million and basic and diluted EPS of -$0.40.
• Revenue for Q2 fiscal 2019 was $654.3 million (latest revenue figure available from SEC snapshot).
• The company is implementing new enterprise resource planning (ERP) systems at CooperVision and CooperSurgical, which is complex and costly.
• Risks include supply chain disruptions, manufacturing capacity constraints, cybersecurity threats, and regulatory compliance challenges.
• The company faces risks from economic and trade sanctions, tariffs, and import/export regulations that may affect operations and competitiveness.
• The company has significant indebtedness with credit facilities containing restrictive covenants.
• Recent news reports indicate Q2 2026 earnings beat with revenue guidance trimmed for FY26, and a Q2 loss impacted by a one-time litigation charge, with revenue rising 8% [N1][N4][N5].
• The company has reached settlement agreements covering over 95% of claimants related to the embryo culture media litigation [S2].